Short answer: Coenzyme Q10 (CoQ10, also called ubiquinone-10) is a fat-soluble lipophilic compound essential to mitochondrial energy production. It shuttles electrons between Complex I/II and Complex III in the inner mitochondrial membrane, generating the proton gradient that drives ATP synthesis. Tissues with high mitochondrial density — heart, kidney, liver, skeletal muscle, brain — carry the highest endogenous CoQ10 concentrations. Per ACVIM 2022 nutritional cardiomyopathy consensus, CoQ10 supplementation has emerging evidence in dogs with chronic valvular disease and dilated cardiomyopathy. Per Freeman 2010 (JVIM) cardiac nutrition review, the practical canine therapeutic dose is approximately 1 mg/kg/day. The KibbleIQ rubric awards positive credit for CoQ10 inclusion in cardiac-support formulations.

What CoQ10 actually is — structure and biological role

Coenzyme Q10 is a benzoquinone derivative with a 10-isoprenoid side chain — the “Q10” designation refers to the 10 prenyl units, distinguishing it from CoQ9 (mouse and rat predominant) and shorter analogs in other species. The structure makes it lipophilic; CoQ10 partitions into the inner mitochondrial membrane and into low-density lipoprotein particles in serum. Per Bhagavan 2006 (Free Radic Res), CoQ10 exists in three redox states: oxidized (ubiquinone), partially reduced (semiquinone radical), and fully reduced (ubiquinol). The redox cycling between these states is the core electron-transport-chain function.

The two principal commercial forms in pet food and supplements are ubiquinone (the oxidized form, the historical commercial standard) and ubiquinol (the reduced form, more bioavailable per Hosoe 2007 Regul Toxicol Pharmacol but more expensive and less stable on the shelf). For pet food applications, ubiquinone is the more common form because of cost and shelf-stability advantages; the body reduces ubiquinone to ubiquinol after absorption, so the form distinction at point-of-purchase matters less than total delivered CoQ10.

Mitochondrial mechanism — electron transport and ATP synthesis

CoQ10 functions as the mobile electron carrier between Complex I (NADH dehydrogenase) and Complex II (succinate dehydrogenase) on the matrix side of the inner mitochondrial membrane and Complex III (cytochrome bc1) on the intermembrane-space side. Electrons from NADH (Complex I) and from FADH2 (Complex II) reduce CoQ10 to ubiquinol, which then donates electrons to Complex III, returning to the oxidized state. Each electron transit pumps protons from the matrix to the intermembrane space, building the gradient that ATP synthase (Complex V) uses to generate ATP per Mitchell 1979 chemiosmotic theory.

The clinical relevance: tissues with high ATP demand — heart muscle (constantly contracting), kidney tubular epithelium (active transport), hepatocytes (biosynthesis), neurons (action-potential propagation), skeletal muscle (during exercise) — have the highest mitochondrial CoQ10 concentrations and the highest sensitivity to CoQ10 depletion. Per Cohen 2014 review, CoQ10 also functions as a lipid-phase antioxidant, protecting mitochondrial membrane lipids from peroxidation by reactive oxygen species generated during normal electron transport leakage.

Cardiac evidence per ACVIM 2022 and Freeman 2010

The strongest canine clinical evidence base for CoQ10 supplementation is in cardiac disease. Per Freeman 2010 (JVIM) cardiac nutrition review, dogs with congestive heart failure (CHF) from chronic valvular disease (CVD) or dilated cardiomyopathy (DCM) commonly show reduced myocardial CoQ10 concentration on biopsy or post-mortem analysis, consistent with the energy-crisis model of failing heart muscle. Per Pion 1992 (Am J Cardiol), CoQ10 supplementation in cardiomyopathic dogs improved fractional shortening and reduced left ventricular end-diastolic volume in non-controlled clinical observations, prompting the formal trials that informed Freeman 2010.

Per ACVIM 2022 nutritional cardiomyopathy consensus statement, CoQ10 is one of several nutritional adjuncts (alongside L-carnitine, taurine, and omega-3 EPA + DHA) with emerging evidence for cardiac support in dogs with diagnosed disease. The consensus emphasizes that nutritional adjuncts complement, not replace, appropriate diagnostic workup and pharmacotherapy. Per ACVIM 2022, the FDA-CVM 2018–2022 grain-free DCM investigation has elevated interest in nutritional cardiac protocols, and CoQ10 is part of the typical adjunctive regimen for affected dogs alongside taurine, carnitine, and marine omega-3. See our taurine explainer and L-carnitine explainer for the cardiac-cofactor companions.

Senior cognition and other emerging applications

Beyond cardiac applications, CoQ10 has secondary canine evidence in senior cognition support. Per Pan 2010 (Br J Nutr) canine cognitive aging study and AAHA 2018 Senior Care Guidelines, mitochondrial dysfunction is a feature of aging neurons, and CoQ10 supplementation in senior dogs has been incorporated into several proprietary cognitive-support diets (Purina Pro Plan Bright Mind, Hill’s Prescription Diet b/d) alongside MCT oil and antioxidant blends. The clinical evidence is less established than the cardiac evidence base; Pan 2010 demonstrated cognitive improvement in senior dogs on a multi-component cognitive-support formula, but did not isolate CoQ10 as a single variable.

Skeletal muscle and exercise applications have been studied in human and equine athletic literature with mixed results per Cohen 2014 review; canine athletic-performance evidence is sparse. Renal tubular CoQ10 supplementation per IRIS 2023 CKD staging has theoretical basis but limited canine clinical-trial evidence. The safest position per ACVIM 2022 and AAHA 2018 is that CoQ10 is well-tolerated supplementation with documented evidence in cardiac disease and emerging evidence in senior cognition; broader applications remain hypothesis-driven.

Dose, bioavailability, and how KibbleIQ scores CoQ10

Per Freeman 2010 (JVIM) and ACVIM 2022 cardiac protocols, the practical canine therapeutic CoQ10 dose for cardiac support is approximately 1 mg/kg body weight/day, with reported ranges of 30 mg/day for small dogs to 200 mg/day for giant breeds. CoQ10 is fat-soluble and absorption improves substantially when taken with a fat-containing meal per Bhagavan 2006 (Free Radic Res), so dosing is typically with food. The dose is generally split between two meals to maintain serum concentration through 24 hours; ubiquinol forms achieve higher serum concentrations at equivalent doses but at higher cost.

The KibbleIQ Dry Kibble Rubric awards positive credit for CoQ10 inclusion in cardiac-support and senior-support formulations when the label declares the form (ubiquinone or ubiquinol) and a guaranteed minimum mg per kg of food. The credit increases when CoQ10 is paired with the cardiac-cofactor companions: taurine, L-carnitine, and marine omega-3 EPA + DHA from salmon oil or krill oil per ACVIM 2022. Foods relevant to cardiac-support nutrition include best dog food for heart disease and best dog food for Dobermans with heart disease. To check what your dog is getting, paste the ingredient list into the KibbleIQ analyzer. CoQ10 supplementation for dogs with diagnosed cardiac disease should always involve the prescribing veterinary cardiologist per ACVIM 2022.